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A number of clinical trials have shown that KRASmutations of colorectal cancer (CRC) can predict a lack of responses to
anti-epidermal growth factor receptor–based therapy. Recently, there have been several studies to elucidatemetabolism
reprogramming in cancer. However, it remains to be investigated howmutated KRAS can coordinate themetabolic shift
to sustain CRC tumor growth. In this study, we found that KRAS mutation in CRC caused alteration in amino acid
metabolism. KRAS mutation causes a marked decrease in aspartate level and an increase in asparagine level in CRC.
Using several human CRC cell lines and clinical specimens of primary CRC, we demonstrated that the expression of
asparagine synthetase (ASNS), an enzyme that synthesizes asparagine from aspartate, was upregulated by mutated
KRAS and that ASNS expression was induced by KRAS-activated signaling pathway, in particular PI3K-AKT-mTOR
pathway. Importantly, we demonstrated that KRAS-mutant CRC cells could become adaptive to glutamine depletion
through asparagine biosynthesis by ASNS and that asparagine addition could rescue the inhibited growth and viability of
cells grown under the glutamine-free condition in vitro. Notably, a pronounced growth suppression of KRAS-mutant CRC
was observed upon ASNS knockdown in vivo. Furthermore, combination of L-asparaginase plus rapamycin markedly
suppressed the growth of KRAS-mutant CRC xenografts in vivo, whereas either L-asparaginase or rapamycin alone was
not effective. These results indicate ASNS might be a novel therapeutic target against CRCs with mutated KRAS.
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Mutations in the KRAS gene are found in various types of cancer
including pancreatic ductal cell adenocarcinoma (PDCA) and colorectal
cancer (CRC). A number of clinical trials have shown that KRAS
mutations in CRC can predict a lack of responses to the anti-epidermal
growth factor receptor (EGFR)–based therapy. The use of anti-EGFR
antibodies, cetuximab and panitumumab, is now limited to patients
with KRAS wild-type CRC [1–3]. Therefore, the development of new
therapy for CRCs with mutated KRAS has been desired clinically.
In recent years, there has been intense interest to understand the
reprogramming of metabolism in cancer [4–7]. One of the metabolic
hallmarks of malignant tumor cells is their dependency on aerobic
glycolysis, known as the Warburg effect [4,5]. The role of KRAS
signaling in the regulation of aerobic glycolysis has been reported in
several types of cancer, although the molecular mechanism behind the
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example, in a PDCA mouse model, mutated KRAS was shown to
maintain tumor growth by stimulating glucose uptake and channeling
glucose intermediates into the hexosamine biosynthesis pathway
(HBP) and pentose phosphate pathway (PPP) [8]. Notably,
knockdown of rate-limiting enzymes in HBP or PPP suppressed
tumor growth, indicating their potential as therapeutic targets. In
CRC cells, the increase of glucose transporter 1 (GLUT1) expression
and glucose uptake was critically dependent on KRAS or BRAF
mutations [9]. Fluorodeoxyglucose (FDG) positron emission tomog-
raphy scans are used to evaluate glucose metabolism by measuring the
uptake of FDG, a glucose analog. We previously reported that CRC
cells with mutated KRAS increased FDG accumulation by upregu-
lation of GLUT1 [10–12]. However, it remains to be investigated
how mutated KRAS can coordinate the metabolic shift to sustain
tumor growth and whether specific metabolic pathways are essential
for the KRAS mutation-mediated tumor maintenance in CRC.
In addition to their glucose dependency, malignant cells rely on
glutamine to support cell growth and survival [13,14]. Glutamine is
one of the most heavily consumed nutrients by cells in culture and the
most abundant amino acid in circulation [15]. Once imported into
the cells, glutamine serves as a carbon source for the tricarboxylic acid
(TCA) cycle and a nitrogen source for nucleotide and nonessential
amino acids. In purine and pyrimidine biosynthesis, glutamine
donates its amino group and is subsequently converted to glutamate.
In turn, glutamate serves as the primary nitrogen source for other
nonessential amino acids by providing the amino group and is
subsequently converted to α-ketoglutarate. The glutamine-derived
α-ketoglutarate replenishes the TCA cycle by providing oxaloacetate
that condenses with acetyl-CoA to maintain the TCA cycle and
support de novo fatty acid biosynthesis. In addition to providing
carbons and nitrogens for biosynthesis, glutamine is also involved in
other cellular processes, including antioxidative stress and the
mammalian target of rapamycin (mTOR) signaling. The spectrum
of glutamine-dependent tumors and the mechanisms by which
glutamine supports cancer metabolism are being actively investigated
[13–18]. In the PDCA mouse model, glutamine supports the growth
of pancreatic cancer through an oncogenic KRAS-regulated metabolic
pathway [19]. Most cells utilize glutamine dehydrogenase (GLUD1)
to convert glutamine-derived glutamate into α-ketoglutarate in the
mitochondria to fuel the TCA cycle. However, PDCA cells rely on a
distinct pathway in which glutamine-derived aspartate is transported
into the cytoplasm and converted to oxaloacetate by aspartate
transaminase (GOT1). In glioma and neuroblastoma, asparagine
plays a critical role in regulating cellular adaptation to glutamine
depletion [20]. Asparagine was shown to be necessary and sufficient
to suppress apoptosis induced by the glutamine withdrawal without
restoring the levels of other nonessential amino acids or TCA cycle
intermediates. Asparagine synthetase (ASNS), the enzyme that
synthesizes de novo asparagine from aspartate and glutamine, was
required to suppress glutamine withdrawal–induced apoptosis, and its
expression was statistically correlated with poor prognosis.
The present study aimed to investigate how mutated KRAS could
regulate metabolic reprograming in CRC and whether metabolic
enzymes associated with mutated KRAS could be novel therapeutic
targets for CRC with KRASmutations. Given that cancer cells rely on
changes in metabolism to support their growth and survival, targeting
the metabolism is a potential cancer treatment strategy. There are a
few reports regarding KRAS mutation-related metabolic alterations inCRC. Here, we revealed that mutated KRAS upregulated ASNS
expression through the PI3K-AKT-mTOR pathway and that ASNS
maintained cell adaptation to glutamine depletion through asparagine
biosynthesis in KRAS-mutant CRCs. Notably, tumor growth of
KRAS-mutant CRC cells was significantly suppressed upon ASNS
knockdown. These results indicate that ASNS might be a novel
therapeutic target for CRCs with mutated KRAS. To our knowledge,
this is the first study to investigate amino acid metabolism associated
with KRAS mutation in CRC.
Materials and Methods
Cell Lines and Reagents
All lines were maintained in Dulbecco's modified Eagle medium
(DMEM) (glucose 25 mM, glutamine 4 mM) (043-30085, Wako)
containing 10% FBS. Media without glutamine were prepared by
using glutamine-free DMEM (glucose 25 mM, glutamine 0 mM)
(043-32245, Wako) containing 10% FBS. LoVo, RKO, COLO-205,
and WiDR cells were supplied from American Type Culture
Collection. The identity of cell line was confirmed by short tandem
repeat analysis (Takara Bio). HCT116, HKh-2, HKe-3, DLD-1, and
DKO-4 cell lines were generated as described previously [21]. All
amino acid were obtained from Wako. U0126 was purchased from
Calbiochem; LY294002 and rapamycin were from Wako.
Measurement of Metabolites
In cell samples, 1 × 106 cells were seeded in 10-cm dishes in DMEM
(25 mM glucose, 4 mM glutamine) containing 10% FBS for 48 hours.
Metabolome analysis was conducted by C-SCOPE package of Human
Metabolome Technologies, Inc., using capillary electrophoresis (CE)
time-of-flight mass spectrometry for cation analysis and CE tandem
mass spectrometry for anion analysis as described previously [11].
Quantitative Reverse Transcription Polymerase Chain
Reaction (RT-PCR) Analysis
Total RNAs were extracted and reverse transcription was performed
with oligo (dT) primer and Transcriptor First Strand cDNA Synthesis
Kit (Roche) according to the manufacturer's instructions. The resulting
cDNA was quantified using StepOnePlus Real-Time PCR System
(Applied Biosystems) and THUNDERBIRD SYBR qPCR Mix
(TOYOBO). Primer sequences are found in Supplementary Table 1.
All transcription levels were normalized to that for ACTB.
Western Blot Analysis
Cells and tissue samples were lysed in lysis buffer (50 mM Tris-HCl,
150 mMNaCl, 1 mM EDTA, 50 mMNaF, 1% NP40) supplemented
with inhibitor cocktails of protease and phosphatase. Primary antibodies
were mouse monoclonal anti-KRAS (Santa Cruz Biotechnology), rabbit
polyclonal anti-ASNS (Abcam), rabbit monoclonal anti–pohospho-p44/
42 kinase (Thr202/Tyr204) (Cell Signaling), rabbit monoclonal
anti-p44/42 kinase (Cell Signaling), rabbit monoclonal anti–
phospho-Akt (Ser473) (Cell Signaling), rabbit monoclonal anti-Akt
(Cell Signaling), rabbit polyclonal anti–phospho-p70 S6 kinase (Thr389)
(Cell Signaling), rabbit polyclonal anti-p70 S6 kinase (Cell Signaling), and
mouse monoclonal anti–β-actin-peroxidase (Sigma-Aldrich).
RNA Interference
To knock down the endogenous expressions of both KRAS and CS,
FlexiTube GeneSolutions (Qiagen) for KRAS (#1: SI03101903, #2:
SI03106824) andCS (#1: SI04147997, #2: SI04184796)were employed,
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used for nonsilencing control. The siRNA (10 nM)was transfectedwith
Lipofectamine RNAiMAX (Invitrogen) according to the manufac-
turer's instruction.
Cell Proliferation Assay
A cell proliferation assay was performed with Cell Counting Kit-8
(CCK-8, Dojindo) according to the manufacturer's instruction. Cells
were cultured in 96-well plates at a density of 5000 cells/well for 48 to
72 hours with or without treatment.
Clonogenic Assay
Cells were seeded in 6-well plates at a density of 200 cells/well in
DMEM (25 mM glucose, 4 mM glutamine) containing 10% FBS.
Ten days later, colonies were fixed in 1% glutaraldehyde and stained
with 0.2% crystal violet for 30 minutes. A colony was defined as a
cluster of at least 50 cells.
Construction of Recombinant Lentivirus
The following oligonucleotides were used to knock down ASNS
expression: shASNS#1-sense, 5′-CCGGATGGTGAAATCTACAAC
CATACTCGAGTATGGTTGTAGATTTCACCAT -
TTTTTG-3′;shASNS#1-antisense, 5′-AATTCAAAAAATGGTGA
AATCTACAACCATACTCGAGTATGGTTGTAGATTTCAC
CAT-3′;shASNS#2-sense, 5′-CCGGTTAGGTGGTCTTTATGCTG
TACTCGAGTACAGCATAAAGACCACCTAATTTTTG-3′;sh
ASNS#2-antisense, 5′-AATTCAAAAATTAGGTGGTCTTTATG
CTGTACTCGAGTACAGCATAAAGACCACCTAA-3′. Each set of
oligonucleotides was annealed and cloned into the AgeI/EcoRI sites of
pLKO.1 (Addgene). pLKO.1-TRC control vector (Addgene) was used as
control. ASNS cDNA was obtained from HCT116 cells. The ASNS
cDNA was cloned into the pLVSIN-CMV (TaKaRa BIO).
Apoptosis Assay
In terminal deoxynucleotidyl transferase-mediated dUTP-FIFC nick
end-labeling (TUNEL) assay, cells were cultured under glutamine-free
DMEM (25 mM glucose, 0 mM glutamine) containing 10% FBS for
72 hours and then fixed in 4% parafolmaldehyde. The number of
TUNEL-positive cells in each of the three slides was counted in five
random fields (magnification, ×400) by software BZ-H3C (Keyence)
and expressed as a percentage of the total cells counted. The activity of
caspase-3 and -7 was measured by using caspase-Glo 3/7 assay
(Promega) according to the manufacturer's protocol. Caspase activity
was normalized to the cell number counted by CCK-8 cell proliferation
assay under the same density and conditions.
Animal Tumor Model
We subcutaneously injected 4-6 × 106 cancer cells into flanks of 4- to
6-week-old female KSN/slc nude mice (JAPAN SLC). Tumor volumes
were calculated using the formula (L × W2) × 0.5, whereL is length and
W is width. At the time of L-asparaginase (L-Asp) and rapamycin
treatment, tumors were established in KSN/slc nude mice by
subcutaneous injection of 5 × 106 of HCT116. Mice with tumors of
150 to 300 mm3 were randomly divides into 4 groups. L-Asp (Kyowa
Hakko KirinCo., Ltd.) was injected daily intraperitoneally at 1500U/kg
for 15 days [22]. Rapamycin (LC Laboratories) was dosed in 4%
ethanol/5% PEG400/5% Tween 80 in water for injection solution
and injected every 5 days intraperitoneally at 3 mg/kg [23]. The control
group was injected every 5 days with an equal volume of the vehicle.
Mice were ethically sacrificed when mean tumor volume reached2000 mm3. Animal experimental studies were conducted in accordance
with our institutional guidelines and approved by the Kyoto University
Animal Care Committee.
Immunohistochemistry
Formalin-fixed, paraffin-embedded sections were stained with
anti-rabbit ASNS (Abcam), anti-mouse CD34 (Abcam), or ant-mouse
Ki67 (Dako) antibody. Antigen retrieval was achieved with microwave in
citrate buffer (pH: 6.0). The Ki67-positive cell numbers were counted in
five random fields (×400). For primary CRC tissue, ASNS immunore-
activity score was determined by the sum of distribution and staining
intensity, as previously described [24]. ASNS expression was defined as
low (total score 0-3) or high (total score 4-7). The distribution was scored
based on the positivity rate as “0” (0%-5%), “1” (5%-25%), “2”
(25%-50%), “3” (50%-75%), or “4” (N75%). The staining intensity was
scored as “0” (no staining), “1” (weakly stained), “2” (moderately stained),
or “3” (strongly stained). Two researchers (K.T. and S.I.) independently
evaluated all immunohistochemistry samples without prior knowledge of
other data. The slides with different evaluations among them were
reinterpreted at a conference to reach the consensus.
Patients, Clinicopathological Data
A total of 93 CRC samples were collected from patients who
underwent tumor resection and with KRAS status checked at Kyoto
University Hospital between April 2009 and September 2013. No
patients received preoperative chemotherapy and radiation therapy. This
study protocol was approved by the institutional review board of Kyoto
University, and patients provided their written consent for data handling.
Statistical Analysis
The statistical significance of differences was determined by Student's
t test or χ2 test. All values were expressed as mean ± standard deviation
(SD). All analyses were two-sided, and differences with a P value of less
than .05 were considered statistically significant in all analyses.
Statistical analyses were conducted with the JMP software (version 9,
SAS Institute, Inc.).
Results
KRAS Mutation-Related Alterations of Amino Acid Metabolism
in Human CRC Cells
To investigate the specific pathway by which mutated KRAS exhibits
metabolic alterations, we used human CRC cell lines with mutated
KRAS (HCT116 and DLD-1) and their isogenic lines in which the
endogenous mutant KRAS allele was disrupted through targeted
homologous recombination [11,21]. HKh-2 and HKe-3 are two
independent HCT116 clones with the mutated KRAS disrupted;
similarly, DKO-4 is a DLD-1 clone with the mutated KRAS disrupted.
These paired cell lines essentially differ only in the mutational status of
KRAS gene, which allowed us to investigate the function of normal or
mutant KRAS proteins at physiological, normally regulated levels. In
addition, these CRC lines also harbor additional mutations in
CTNNB1 and TGFβ-RII genes [25,26]; therefore, KRAS signaling
can be studied in the context of other gene mutations commonly found
in CRC. Using these paired lines, we previously reported that mutated
KRAS caused higher FDG accumulation by upregulation of glucose
uptake through GLUT1 [10–12]. To further dissect the metabolic
alterations caused by mutated KRAS, CE mass spectrometry (CE/MS)
metabolomic analysis was performed to comprehensively characterize
intracellular metabolites inHCT116 paired lines. This analysis revealed
Figure 1. Metabolic alterations caused by KRAS mutations in colorectal cancer cells. (A) Heat map shows metabolic changes of amino
acid in KRAS-mutant CRC cells (HCT116) and their isogenic counterparts containing wild-type KRAS allele (HKh-2 and HKe-3). Metabolome
analysis (CE/MS) was performed from triplicates for each condition and normalized to cell number. Cells were maintained in DMEM
(25 mM glucose, 4 mM glutamine) containing 10% FBS for 48 hours. WT, KRAS wild type; MT, KRAS mutant. (B) Relative metabolite
levels are expressed as fold change compared with metabolite concentration of HCT116. Mean; bars, ± SD, n = 3 (Student's t test;
*P b .05). Ala, alanine; Arg, arginine; Asn, asparagine; Asp, aspartate; Cys, cysteine; Gln, glutamine; Glu, glutamate; Gly, glycine; His,
histidine; Ile, isoleucine; Leu, leucine; Lys, lysine; Met, methionine; Phe, phenylalanine; Ser, serine; Thr, Threonine; Trp, tryptophan; Tyr,
tyrosine; Val, valine. (C) Schematic representation of glutaminemetabolism. α-KG, α-ketoglutarate; OAA, oxaloacetate; Pyr, pyruvate; Glc,
glucose; AcCoA, acetyl-CoA; Cit, citrate. (D) Quantitative RT-PCR showing relative mRNA levels for metabolic enzymes associated with
glutamine metabolism. KRAS-mutant cells (HCT116 and DLD-1) and their isogenic counterpart containing wild-type KRAS allele (HKh-2,
HKe-3, and DKO-4). Mean; bars, ± SD, n = 3 (Student's t test; *P b .05). (E) Western blot photographs of ASNS and β-actin (Actin) (top)
and quantified data for ASNS (bottom) (normalized with β-actin). (F) Quantitative RT-PCR showing relative mRNA levels for metabolic
enzymes associated with glutamine metabolism. HCT116 cells (left) and DLD-1 cells (right) were treated separately with two independent
siRNA constructs (#1 and #2) targeting KRAS and NC siRNA. Mean; bars, ± SD, n = 3 (Student's t test; *P b .05).
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such as glycolysis, PPP, TCA, and most significantly the amino acid
pathway (Figure 1A and Supplementary Figure S1A). In particular,
aspartate level in HCT116 with mutated KRAS was significantly lower
compared with that in their isogenic counterparts containing wild-type
KRAS allele (HKh-2 and HKe-3). In contrast, asparagine level was
significantly higher in HCT116 than in HKe-3 (Figure 1B). The
asparagine/aspartate ratio was significantly higher in HCT116 than in
HKh-2 and HKe-3 (Supplementary Figure S1B).
Upregulation of Asparagine Synthetase in KRAS-Mutant CRCs
Through the PI3K-AKT-mTOR Pathway
Recently, it has been reported that KRAS mutation in PDCA cells
regulates the glutamine metabolism through its conversion to aspartate,
thereby supporting tumor growth by maintaining the cellular redox
balance [19]. Glutamine is transported into the cytoplasm by neutral
amino acid transporter (ASCT2) and is subsequently converted to
glutamate by glutaminase (GLS) at mitochondria. Thereafter,
glutamate can be converted to α-ketoglutarate by GLUD1 to replenish
the TCA cycle by GLUD1 or converted to nonessential amino acids
such as aspartate and alanine by transaminases. In PDCA, glutamic-
oxaloacetic transaminase 2 (GOT2) was identified as the transaminase
associated with mutated KRAS at mitochondria [19]. Glutamine-
derived aspartate is transported into the cytoplasm where it can be
converted to asparagine by ASNS or to pyruvate by GOT1, malic
enzyme 1, and malate dehydrogenase 1 (Figure 1C). A recent report
demonstrated that mutated KRAS controlled the reprograming of
glutamine metabolism by decreasing GLUD1 and increasing GOT1 in
PDCA [19]. To identify the metabolic enzymes associated with the
reprograming of glutamine metabolism in CRC, we first screened the
expression of the above-mentioned enzymes by quantitative RT-PCR
analysis. Notably, ASNS mRNA expression in the parental KRAS-
mutant cells (HCT116 and DLD-1) was about 2.5- to 5-fold higher
than in their isogenic wild-type KRAS cells (Figure 1D). By Western
blotting, we also confirmed that ASNS protein level was about 2.5- to
10-fold higher in the parental KRAS-mutant cells than in the
corresponding isogenic wild-type KRAS cells (Figure 1E). To further
validate the relationship between ASNS andKRAS, we performed RNA
interference experiments. We introduced two kinds of different siRNA
constructs targeting KRAS (referred to as siKRAS#1 and #2) into
HCT116 and DLD1 cells (Supplementary Figure S2A and B) and
verified that both siKRAS constructs dramatically decreased mRNA
expression of ASNS but not GLUD1 or GOT1 (Figure 1F).
KRAS protein activates its downstream signaling pathways, such as
the Raf/MEK/ERK and PI3K/Akt pathways, leading to malignant
transformation.Weused a specific inhibitor of each pathway to examine
which pathway regulates the induction of ASNS expressionmediated by
mutated KRAS. HCT116 and DLD-1 cells were treated with a MEK
inhibitor (U0126, 20 μM), a PI3K inhibitor (LY294002, 50 μM), or
an mTOR inhibitor (rapamycin, 20 nM). A Western blot analysis
showed that ASNS expression was dramatically inhibited by LY294002
and rapamycin but not U0126 (Figure 2A), suggesting that ASNS
expression is correlated with the PI3K/AKT/mTOR pathway in
KRAS-mutant cells (HCT116 and DLD-1).
Based on these findings, we hypothesized that ASNS expression in
CRC is regulated by mutated KRAS. We therefore determined the
expression level of ASNS in several human CRC cell lines. HCT116,
DLD-1, and LoVo cells bear a mutantKRAS allele at codon 13 (G13D),
whereas RKO, COLO-205, andWiDr cells bear the wild-typeKRAS. AWestern blot analysis showed that KRAS-mutant cells constitutively
expressed high level of ASNS, whereas wild-type KRAS cells exhibited
little to no ASNS expression (Figure 2B). To further investigate the
relationship between KRAS status and ASNS expression, we next
examined clinical specimens of human primary CRC by immunohis-
tochemistry. Representative cases of CRCs bearing mutated and
wild-type KRAS are shown in Figure 2C. Of a total of 93 primary
CRC patients, 50% (46 of 93) were high for ASNS, whereas 50% (47 of
93) were low (Table 1). Patients were classified into two groups based on
theirKRASmutational status: patients with mutatedKRAS (n = 39) and
those with wild-typeKRAS (n = 54). ASNS expression was high in 74%
(29 of 39) of patients with mutated KRAS, whereas it was low in 31%
(17 of 54) of those with wild-type KRAS, with a significant correlation
between mutated KRAS and ASNS expression (odds ratio, 6.31;
P b .001, Figure 2D). ASNS expression was not correlated with age, sex,
tumor location, tumor size, T-category, N-category, and M-category
(Table 1). Taken together, KRAS status is one of the key regulators of
ASNS expression in CRC.
The Role of ASNS in Cell Adaptation to Glutamine Depletion
in KRAS-Mutant CRC Cells
ASNS is the enzyme that synthesizes de novo asparagine from
aspartate using glutamine as a nitrogen source. In human glioma and
neuroblastoma, it was recently reported that asparagine was essential to
suppress apoptosis induced by glutamine withdrawal without restoring
the levels of other nonessential amino acids or TCA cycle intermediates
and that ASNS knockdown led to cell death even in the presence of
glutamine [20]. To evaluate whether KRAS mutational status of CRC
cells could affect their addiction to glutamine, we tested the clonogenic
assay. In the absence of glutamine, colony number of KRAS-mutant
cells (HCT116) was significantly higher than the isogenic wild-type
KRAS cells (HKh-2 and HKe-3) (Figure 3A), indicating that KRAS-
mutant CRC cells were more resistant to glutamine deprivation than
wild-type KRAS CRC cells. Citrate synthase (CS) is a TCA cycle
enzyme that catalyzes the formation of citrate from oxaloacetate and
acetyl-CoA. CS siRNA was identified to be a suppressor of glutamine
withdrawal–induced apoptosis by reducing TCA cycle activity and
redirecting oxaloacetate for synthesis of aspartate and asparagine [20].
Consistent with the findings in human glioma and neuroblastoma, we
found that CS knockdown using siRNA prevented glutamine
withdrawal–induced apoptosis and suppression of cell proliferation in
HCT116 cells (Supplementary Figure S3, A–C), although CS
expression level was not correlated with KRAS mutation (Supplemen-
tary Figure S3D). These data further support the critical role of this
pathway in glutamine metabolism and tumor growth.
To further investigate the role of ASNS, two lentiviral shRNA
constructs targeting ASNS (referred to as shASNS#1 and shASNS#2)
were introduced into HCT116 cells (Supplementary Figure S4A).
Under the condition of glutamine depletion, both shASNS constructs
significantly decreased cell proliferation compared with the control in
a dose-dependent manner (Figure 3B), although cell proliferation was
not affected under sufficient amount of glutamine (4 mM Gln)
(Supplementary Figure S4B). Similarly, under the glutamine-free
condition, the colony number of shASNS transfectants was
significantly lower than that of the control cells in the clonogenic
assay (Figure 3C). We also found that the number of apoptotic cells
was significantly higher in shASNS transfectants than the control cells
(Supplementary Figure S4C). To test whether these effects of shRNAs
were specific, we further performed rescue experiments. Namely, the
Figure 2. ASNS expression in CRC. (A) Western blot analyses of HCT116 (left) and DLD-1 (right) treated with dimethyl sulfoxide (DMSO),
20 μM U0126 (MEK inhibitor), 50 μM LY294002 (PI3K inhibitor), or 20 nM rapamycin (mTOR inhibitor) for 48 hours. Protein levels were
normalized to β-actin (Actin). Densitometry values were expressed as fold change compared with DMSO treating cells. (B) Western blot
analysis of ASNS expression in several human CRC cell lines. Densitometry values were expressed as fold change compared with
HCT116. (C) H&E and immunohistochemical staining for ASNS in primary CRCs. Upper panels show serial sections of a KRAS-mutant CRC
case, whereas lower panels show those of a wild-type KRAS one. Scale bar, 50 μm. (D) Relationship between KRASmutational status and
ASNS expression in 93 primary CRC samples.
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shASNS#2 cells in which the targeted sequence was located at the
3′-untranslated region (3′UTR) (Supplementary Figure S4D). Both
the proliferation rate and clonogenic growth of shASNS transfectants
under the glutamine-free condition were significantly rescued by
ASNS overexpression (Supplementary Figure S4, E and F). To
evaluate whether the growth-inhibitory effects of shASNS constructs
were recovered by exogenous addition of asparagine (the ASNS
product), we next tested the effect of asparagine addiction to the
medium and found that 0.1 mM asparagine was sufficient to recover
the growth inhibition of shASNS transfectants in the cell proliferation
(Figure 3, D and E) and clonogenic assays (Supplementary
Figure S5A). Consistently, asparagine addition significantly suppressed
the apoptosis of shASNS transfectants under the glutamine-free
condition (Figure 3F). Furthermore, we found that the significant
growth recovery of shASNS transfectants under the glutamine-freecondition was observed only upon asparagine addition but not other
amino acids (Figure 3G), indicating the specificity of asparagine-
mediated rescue of cell survival. Together, these data indicate that ASNS
upregulation caused by KRAS mutation maintains cell adaptation to
glutamine depletion through asparagine biosynthesis.
Suppression of Tumor Growth In Vivo of KRAS-Mutant CRC
Cells by ASNS Inhibition
As further investigation of the importance of ASNS inKRAS-mutant
CRC cells, we assessed the ability of CRC cells to grow as xenografts
in vivo. Consistent with results obtained from the in vitro studies,
shASNS#1 construct significantly reduced tumor growth of HCT116
cells compared with the control cells (Figure 4A and Supplementary
Figure S4G). Immunohistochemical analysis indicated that the number
of Ki67-positive tumor cells was significantly lower in shASNS#1
transfectant tumors than in the control tumors, especially in the location
Table 1. Univariate Analysis of Factors Associated With Expressions of ASNS
ASNS
High (n = 46) Low (n = 47) P
Mean, age ± SD (y) 69.5 ± 10.7 69.5 ± 10.8 .63
Sex
Male 28 27 .84
Female 18 20
Location
Colon 32 33 1
Rectum 14 14
Mean tumor size (mm) .26
≥50 24 19
b50 22 28
UICC-TMN stage
I/II 20 27 .22
III/IV 26 20
T-category
Negative 12 12 1
Positive 34 35
M-category
Negative 39 39 1
Positive 7 8
N-category
Negative 22 29 .21
Positive 24 18
KRAS
Wild type 17 37 b.001
Mutated 29 10
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andC). We also measured the intratumoral vessel density and found no
difference between shASNS#1 transfectant tumors and the control
(Figure 4D). Furthermore, we also performed rescue experiments
in vivo and found that the reduced tumor growth of shASNS#2
transfectant was significantly recovered by ASNS overexpression
(Supplementary Figure S5B).
Combination Treatment of L-Asp Plus Rapamycin
Given the importance of glutaminemetabolism in themaintenance of
tumor growth, we speculated that KRAS-mutant CRC cells might be
sensitive to the inhibition of anabolic glutamine metabolism. Therefore,
we determined whether ASNS inhibition combined with depletion of
plasma glutamine and asparagine could be used as a novel therapeutic
strategy to treat KRAS-mutant CRCs. L-Asp, an FDA-approved drug
widely used to treat acute lymphoblastic leukemia (ALL), has activities of
both asparaginase and GLS [27,28]. The inhibitory effect of L-Asp on
the cell proliferation and clonogenic growth in vitro was significantly
higher in shASNS transfectants than in the control cells (Figure 5, A
and B). A potent ASNS inhibitor capable of inhibiting the intracellular
asparagine biosynthesis in vivo is yet to be developed [20,29,30]. We
found that the upregulation of ASNS expression mediated by the
mutated KRAS was dramatically suppressed by rapamycin (Figure 2A),
and so we examined whether rapamycin could synergize with L-Asp in
the clonogenic assay. In both the clonogenic and cell proliferation assays,
the combination of L-Asp plus rapamycin suppressed cell growth of
KRAS-mutant CRCs (HCT116 and DLD-1) more prominently than
L-Asp or rapamycin alone did (Figure 5,C andD). We next assessed the
sensitivity of HCT116 xenografts to the combination of L-Asp plus
rapamycin in vivo. Mice with tumors of 150 to 300 mm3 were
randomly divided into 4 groups and treated with vehicle, L-Asp alone
(1500 U/kg), rapamycin alone (3 mg/kg), or the combination of bothdrugs. Consistent with the in vitro results, tumor growth of xenografts
was strongly suppressed by the combination of L-Asp plus rapamycin,
although treatments using each single drug showed no or marginal effect
(Figure 5E). We examined ASNS expression in vivo of each xenograft
and confirmed that rapamycin significantly suppressedASNS expression,
whereas L-Asp upregulated its expression (Supplementary Figure S6, A
and B). Taken together, these results indicate that the combination
therapy using L-Asp plus ASNS inhibitor could be an effective strategy to
treat KRAS-mutant CRC by impairing the glutamine metabolism.
Discussion
Metabolic alterations have recently emerged as one of the cancer
hallmarks [4–7].Major tumor suppressors and oncogenes have intimate
connections with the metabolic pathways. KRAS mutations occur in a
variety of human malignancies, most frequently in PDCA, non–small
cell lung cancer, and CRC. Recent studies indicate that the role of
KRAS in cancer metabolism is complex [31,32]. In an inducible
KRASG12D-driven PDCA mouse model, KRASG12D played a vital role
in controlling tumor metabolism by increasing glucose uptake, which
resulted in activation of protein glycosylation and ribose biogenesis
through the HBP and nonoxidative PPP, respectively [8]. Glucose
deprivation can increase the mutation rate of KRAS in CRC, which
facilitates glucose uptake through the induction of GLUT1 [9].
Moreover, in KRAS-mutant CRC cell lines, vitamin C treatment was
recently shown to induce a substantial increase in endogenous reactive
oxygen species mediated by increased uptake of the oxidized vitamin C
through GLUT1, which inhibited glycolysis at GAPDH to result in an
energy crisis and ultimately cell death [33]. We previously reported that
glucose uptake, as measured by FDG positron emission tomography
scans, was associated with KRAS mutations and GLUT1 expression in
primary and metastatic CRCs [10,12] and that KRAS-mutant CRC
cells increased FDG accumulation by upregulating GLUT1 and
HIF-1α under hypoxic conditions [11]. Tumorigenesis induced by
mutated KRAS was also shown to be dependent on the function of
mitochondria to generate reactive oxygen species, particularly through
elevated glutamine metabolism [34]. In the present study, using
comprehensive CE/MS metabolomics analysis, we found that mutated
KRAS significantly altered the amino acid metabolism of CRC cells
(Figure 1A and Supplementary Figure S1A). Most importantly,
mutated KRAS markedly decreased the aspartate level and increased
the asparagine level (Figure 1B and Supplementary Figure S1B). In
addition, we demonstrated that the expression of ASNS, the enzyme
that synthesizes asparagine from aspartate, was upregulated by mutated
KRAS in CRC using multiple human CRC cell lines and clinical
specimens of human primary CRC (Figure 2, B–D) and that ASNS
expression was regulated by a KRAS-activated pathway, specifically the
PI3K-AKT-mTOR pathway (Figure 2A). ASNS was reported to be
activated by mutated p53, protein limitation, and tumor microenvi-
ronment stress [35–37]. ASNS was reported to be associated with the
sensitivity of L-Asp in the treatment of ALL [35,38]. In addition, ASNS
was also reported to be associated with the sensitivity of cisplatin and
with clinical prognosis in some types of solid cancer [20,24,39–42]. To
our knowledge, this is the first study to investigate the relationship
between CRC and ASNS.
In addition to the well-established role of an altered glucose
metabolism in cancer, recent studies have also elucidated the role of
amino acid metabolism, especially glutamine, in cell proliferation and
maintenance [13,14]. Although the molecular mechanism of glutamine
addiction in cancer cells is unknown, several oncogenic mutations or
Figure 3. ASNS maintains cell adaptation to glutamine depletion in KRAS-mutant CRC cells. (A) Clonogenic assay with HCT116 and their
isogenic wild-type KRAS cells (HKh-2 and HKe-3). Cells weremaintained under 4mMor 0mMglutamine (Gln) condition containing 10% FBS
for 10days. Each colony number in 0mMGlnwas normalized to that in 4mMGln.Mean;bars,±SD, n = 3 (Student's t test; *P b .05). (B) Cell
proliferation measured by CCK-8 assay. HCT116 cells transfected with control or two independent shASNS vectors were maintained under
various Gln concentration containing 10% FBS for 48 hours. Viability in each condition was normalized to that in 4 mMGln. Student's t test;
*P b .05. (C) Clonogenic assay with HCT116 transfected with control or two independent shASNS vectors. Cells weremaintained under 4 or
0mMGln condition containing10%FBS for 10days. Eachcolonynumber in 0mMGlnwasnormalized to that in 4mMGln.Mean;bars,±SD,
n = 3 (Student's t test; *P b .05). (D) Cell proliferation measured by CCK-8 assay. HCT116 transfected with control or two independent
shASNS vectors. Cellsweremaintained under various concentrations of Asn and 0mMGln containing 10%FBS for 48 hours. Viability in each
condition was normalized to that in 4 mM Gln. Student's t test; *P b .05. (E) Cell proliferation measured by CCK-8 assay. HCT116 cells
transfectedwith control or two independent shASNS vectors weremaintained under either 0mMGln or 0mMGln+ 0.1mMAsn containing
10% FBS for 48 hours. Viability in each condition was normalized to that in 4 mM Gln. Mean; bars,± SD, n = 3 (Student's t test; *P b .05).
(F) Caspase 3/7 activities. HCT116 transfected with control or two independent shASNS vectors were maintained under either 0 mM Gln or
0 mMGln+ 1mMAsn containing 10% FBS for 48 hours. Caspase 3/7 activity was normalized to the cell viability measured by CCK-8 assay
under the samedensity and conditions.Mean; bars,±SD, n = 3 (Student's t test; *P b .05, control vector versus shASNS vectors; **P b .05,
0 mMGln versus 0 mM Gln+ 1 mMAsn). (G) Cell proliferation measured by CCK-8 assay. HCT116 cells transfected with control or shASNS
vectors were maintained under 0 mM Gln plus each amino acid (0.5 mM) containing 10% FBS for 48 hours. Viability in each condition was
normalized to that in 4 mM Gln. Mean; bars, ± SD, n = 3 (Student's t test; *P b .05, NS: not significant).
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Figure 4. ASNS knockdown inhibits tumor growth in vivo. (A) Xenograft size of HCT116 cells transfected with control or shASNS vector. A
total of 4 × 106 cells were subcutaneously injected into the flank of 4- to 6-week-old female nude mice, and then tumor volumes were
measured 2 times per week (each group, n = 5). Representative images of tumors are shown. (B) H&E and immumohistochemical
staining for ASNS, CD34, and Ki67 in xenograft tumors. Upper panels show serial sections of control tumors, whereas lower panels show
those of shASNS-transfected tumors. Scale bar, 50 μm. (C) Ki67-positive cell density. Cell numbers were counted in five random fields
(each group, n = 3). Mean; bars, ± SD (Student's t test; *P b .05). (D) Microvessel density. CD34-positive cells were counted in five
random fields (each group, n = 3). Mean; bars, ± SD (Student's t test; NS: not significant).
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example, Myc is able to increase glutamine metabolism by upregulating
GLS expression, which leads to glutamine entry into the TCA cycle as
α-ketoglutarate [43]. Moreover, recent studies have revealed that
PDCA, glioma, and neuroblastoma metabolize glutamine in a manner
that is different from canonical GLUD1 pathway (conversion ofglutamine-derived glutamate into α-ketoglutarate by GLUD1 to fuel
the TCA cycle) [19,20]. In PDCA, mutated KRAS contributes to
glutamine dependency by using glutamine-derived aspartate to produce
oxaloacetate via GOT1 in the cytoplasm. Oxaloacetate is subsequently
converted into malate and then to pyruvate to maintain a high
NADPH/NADP+ ratio for redox homeostasis [19]. In glioma and
Figure 5. Inhibition of ASNS suppresses in vivo tumor growth of KRAS-mutant CRC cells. (A) Cell proliferation measured by CCK-8 assay.
HCT116 cells transfected with control or two independent shASNS vectors were treated with various concentrations of L-Asp for
72 hours. Viability in each condition was normalized to the control. Mean; bars, ± SD, n = 3 (Student's t test; *P b .05). (B) Clonogenic
assay with HCT116 transfected with control or two independent shASNS vectors. Cells were treated by various concentrations of L-Asp
for 10 days. Each colony number was normalized to that under no treatment of L-Asp. Mean; bars,±SD, n = 3 (Student's t test; *P b .05).
(C) Cell proliferation measured by CCK-8 assay. HCT116 and DLD-1 cells were treated by DMSO, rapamycin (20 nM), L-Asp (0.25 U/ml), or
rapamycin (20 nM) + L-Asp (0.25 U/ml) for 48 hours. Viability in each condition was normalized to that of DMSO treatment group. Mean;
bars, ± SD, n = 3 (Student's t test; *P b .05, compared with DMSO treatment group; **P b .05, compared with combination treatment
group [rapamycin + L-Asp]). (D) Clonogenic assay. HCT116 and DLD-1 cells were treated by DMSO, rapamycin (20 nM), L-Asp (0.1 U/ml),
or rapamycin (20 nM) + L-Asp (0.1 U/ml). Each colony number was normalized to that of DMSO treatment group. Mean; bars,± SD, n = 3
(Student's t test; *P b .05, compared with DMSO treatment group; **P b .05, compared with combination treatment group [rapamycin +
L-Asp)]. (E) Xenograft size of HCT116 cells treated with vehicle, L-Asp, rapamycin, or L-Asp + rapamycin. HCT116 subcutaneously injected
into the flank of 4- to 6-week-old female nude mice. Tumors of 150 to 300 mm3 were randomly divides into 4 groups: vehicle, L-Asp alone
(1500 U/kg), rapamycin alone (3 mg/kg), and combination of both drugs groups. We injected L-Asp daily and rapamycin every 5 days
intraperitoneally for 15 days. Relative tumor volumewas calculatedbasedon the tumor volumeat the start day of each treatment. Eachgroup,
n = 5. Mean; bars, ± SD, Student's t test; *P b .05, compared with combination treatment group (rapamycin + L-Asp).
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glutamine withdrawal by reducing TCA cycle activity and diverting
oxaloacetate into aspartate and asparagine, which indicates that
maintaining TCA cycle is not the primary mechanism of apoptosis
suppression by glutamine metabolism. Glutamine-dependent aspara-
gine synthesis by ASNS is required to suppress apoptosis induced by
glutamine withdrawal [20]. However, the role of the glutamine
metabolism inCRCs has not been fully elucidated. In the present study,
we demonstrated that KRAS-mutant CRC cells could become adaptive
to glutamine depletion through asparagine biosynthesis by ASNS and
that addition of exogenous asparagine rescued the growth inhibition
and cell death under the glutamine-free condition (Figure 3). It was
recently reported that asparagine addition to glutamine-deprived cells
altered the transcriptional response, thereby suppressing the induction
of apoptotic regulators of the unfolded protein response effectors
CHOP and XBP1 [20]. Moreover, a recent report has indicated that
intracellular asparagine promotes cancer cell proliferation through
uptake of amino acids (especially serine, arginine, and histidine) which
are involved in protein and nucleotide synthesis [44]. Taken together,
these results suggest important roles of asparagine in controlling protein
synthesis and turnover in CRC. We observed that mutated KRAS did
not alter the expression of GLUD1 and GOT1 in CRC (Figure 1, D
and F), although mutated KRAS was reported to cause a decrease of
GLUD1 and an increase of GOT1 in PDCA [19], indicating that the
multifaceted roles of KRAS in metabolism are cell type dependent.
The importance of asparagine to cell survival has already been
established through the use of L-Asp as a therapy for ALL. Leukemic
cells lack the constitutive expression of ASNS and the ability to
synthesize asparagine from glutamine and thus are dependent on
exogenous asparagine to maintain their viability. In contrast, most solid
tumors express ASNS and synthesize asparagine from glutamine [37],
and L-Asp has not been proven as an effective therapy. The effects of
ASNS in tumorigenesis also seem to be cell type dependent. It was
recently reported that ASNS silencing produced the strongest inhibitory
effect on sarcoma growth in a functional genomic shRNA-based
screening of mouse sarcomas generated by oncogenic KRAS and
disruption ofCdkn2a[22]. ASNS silencing in sarcoma cell lines reduced
the percentage of S phase cells and impeded new polypeptide synthesis.
The effects of ASNS silencing in sarcoma cells were reversed by
exogenous supplementation of asparagine. Moreover, ASNS inhibition
significantly slowedmouse sarcoma growth in vivo only when combined
with asparaginase, implicating asparagine-promoted cellular adaptation
to metabolic stress such as glutamine depletion. In the present study,
ASNS inhibition significantly suppressed tumor growth in vivo of
KRAS-mutant CRC cells (HCT116) (Figure 4A and Supplementary
Figure S4G). Normal serum asparagine levels of mice and humans were
reported to be 0.052 mM and 0.046 mM, respectively [22,45]. In
shASNS transfectants, we found that the growth-inhibitory effects
in vitro were recovered by exogenous addition of 0.1 mM asparagine
(Figure 3, D–G and Supplementary Figure S5A). Therefore, we
examined whether the physiological concentration of asparagine
(i.e., 0.05 mM) could recover the growth-inhibitory effects and
found that 0.05mM asparagine was not sufficient to recover the growth
inhibition in vitro (Supplementary Figure S5C). In addition, the tumor
cells within solid tumors in vivo are under a state of poorer nutrient,
especially in the regions distant from tumor blood vessels. L-Asp
treatment could diminish serum asparagine levels of mice and humans
down to 0.004 and 0 mM, respectively [22,45]. ASNS induction by
L-Asp treatment was reported to be the resistance mechanism of L-Aspin the treatment of ALL [46]. Currently, ASNS inhibition has only been
tested in L-Asp–refractory cases of ALL. ASNS inhibition induced cell
death of glioblastoma cell lines in culture only when exogenous
asparagine was absent [20]. Such inhibitorsmaywell exhibit a therapeutic
effect in other cancers when used together with L-Asp. A potent ASNS
inhibitor available for use in vivo has not been developed yet [20,29,30]
and is desirable clinically. In the present study, we found that L-Asp alone
was not effective toKRAS-mutant xenografts (Figure 5E) and that ASNS
protein expression was upregulated upon treatment with in the L-Asp
alone (Supplementary Figure S6, A and B). We also demonstrated that
rapamycin significantly suppressed ASNS expression in vitro and in vivo
(Figure 2A and Supplementary Figure S6, A and B) and that the
combination of L-Asp plus rapamycin markedly suppressed tumor
growth in vivo (Figure 5E). Taken together, these results suggest that the
combination of L-Asp plus rapamycin might be effective even in CRC
with elevated ASNS expression. L-Asp and a rapamycin derivative,
temsirolimus, were approved by FDA for the treatment of ALL and renal
cell carcinoma, respectively [27,28,47]. It is notable that the safety of
L-Asp and temsirolimus has already been assessed in these targeted
diseases. However, native L-Asp derived from Escherichia coli cannot be
acceptable in adult solid cancer patients due to its side effect [41]. A new
L-Asp encapsulated within erythrocytes appears to improve safety
compared with the native L-Asp [48], and a clinical trial is ongoing to
evaluate the new L-Asp in PDCA metastatic setting [32]. Furthermore,
chemical targeting of asparagine availability can also have a therapeutic
value in several types of solid tumors including CRC.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.neo.2016.09.004.
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